RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma Ltd. has announced a new U.S. patent for Opaganib, targeting the treatment of COVID-19, with validity extending through 2041. The patent covers the identification of a novel biomarker predictive of the drug’s effectiveness and follows published data indicating significant patient improvements, including oxygenation, reduced intubation needs, and mortality rates. Opaganib is a first-in-class, orally administered drug with potential applications in several diseases, and is part of U.S. government collaborations for pandemic preparedness.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
